

High levels of TK1 predicts early death in prostate cancer

A new peer-reviewed article about thymidine kinase 1 (TK1) has been published in the journal *The Prostate*. The 30-year study shows an association between high initial levels of serum TK1 and mortality. Prostate cancer-specific survival was on average 9 years shorter for patients with high sTK1 levels than patients with low levels at screening.

Researchers at the Karolinska Institute and Karolinska University Hospitals analyzed 30-year-old blood samples from a prostate screening study conducted at Södersjukhuset in 1988. TK1 was analyzed with AroCells TK 210 ELISA test and the results were compared to long-term patient outcomes and survival. A significant correlation between elevated TK1 at screening and subsequent early death from prostate cancer was found.

The article *Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer* can be found at <https://doi.org/10.1002/pros.24335>

"Results of this study in combination with earlier publications; show that AroCells TK 210 ELISA can assist in the diagnosis, treatment efficiency evaluation, and outcome predictions in different cancers. But also, overall survival expectations for patients. Our aim is to use TK 210 ELISA in a clinical setting and make TK1 a gold standard in personalized medicine", says Anders Hultman, CEO of AroCell.

Earlier studies with shorter follow-ups and different endpoints are consistent with the results obtained. Another Swedish study compared a panel of biomarkers on a cohort of newly diagnosed men and was able to show that TK1 predicted death in prostate cancer in the short-term setting, within 3 years of sampling, better than, for example, PSA. In a Finnish prostate cancer study, the group with metastases had a statistically significantly higher TK1 value and in survival analysis, TK1 was a statistically significant predictor of death, cancer-specific and general.

Contacts

Anders Hultman, CEO
Phone: +46(0)18 50 30 20
E-mail: anders.hultman@arocell.com

About TK 210 ELISA

AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. The ELISA format is simple and robust, requires no special instrumentation to perform and can easily be incorporated into standard laboratory processes. By utilizing monoclonal antibodies specific for the TK1 epitope TK 210, AroCell TK 210 ELISA brings improved sensitivity and specificity to the assay of this key biomarker. AroCell TK 210 ELISA provides new opportunities for studying cellular proliferation, disruption, and monitoring of therapy response and relapse in subjects with haematological and solid tumours.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare and established in various markets. In oncology, AroCell uses various biomarkers, TK1 and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Attachments

[High levels of TK1 predicts early death in prostate cancer](#)